Seven Mile Advisory acquired a new stake in AstraZeneca PLC (OTCMKTS:AZNCF – Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 4,207 shares of the company’s stock, valued at approximately $738,000.
Other hedge funds also recently made changes to their positions in the company. Hughes Financial Services LLC acquired a new position in shares of AstraZeneca during the fourth quarter worth $34,000. Mascoma Wealth Management LLC acquired a new stake in AstraZeneca during the 4th quarter valued at $46,000. Triumph Capital Management purchased a new stake in AstraZeneca during the 4th quarter worth $75,000. Elyxium Wealth LLC purchased a new stake in AstraZeneca during the 4th quarter worth $102,000. Finally, Redmont Wealth Advisors LLC acquired a new position in AstraZeneca in the 4th quarter worth $122,000. Hedge funds and other institutional investors own 40.87% of the company’s stock.
AstraZeneca Price Performance
OTCMKTS:AZNCF opened at $187.10 on Monday. The firm has a 50-day moving average of $187.10 and a two-hundred day moving average of $186.00. AstraZeneca PLC has a 1-year low of $122.26 and a 1-year high of $195.00.
AstraZeneca Company Profile
AstraZeneca (OTCMKTS:AZNCF) is a global biopharmaceutical company that focuses on the discovery, development, manufacturing and commercialization of prescription medicines. The company’s research and development efforts are concentrated in three main therapeutic areas: oncology; cardiovascular, renal and metabolism; and respiratory, inflammation and autoimmunity. AstraZeneca’s product portfolio includes targeted therapies for lung and breast cancers, novel agents for heart failure and chronic kidney disease, and inhaled treatments for asthma and chronic obstructive pulmonary disease.
The company was formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group, creating one of the world’s largest pharmaceutical firms.
Further Reading
- Five stocks we like better than AstraZeneca
- 3 ETFs Giving Ready-Made Access to the Discounted International Small-Cap Space
- What to Expect From Q2 Earnings as Tech Strength Broadens
- Viasat’s Orbiting Profits: Space Force Jackpot?
- Robinhood Wants a Bigger Role in IPOs—Here’s Why It Matters
Want to see what other hedge funds are holding AZNCF? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (OTCMKTS:AZNCF – Free Report).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.
